DK2367840T3 - Enkelt-kædede antiparallelle coiled-coil proteiner - Google Patents
Enkelt-kædede antiparallelle coiled-coil proteiner Download PDFInfo
- Publication number
- DK2367840T3 DK2367840T3 DK09774880.0T DK09774880T DK2367840T3 DK 2367840 T3 DK2367840 T3 DK 2367840T3 DK 09774880 T DK09774880 T DK 09774880T DK 2367840 T3 DK2367840 T3 DK 2367840T3
- Authority
- DK
- Denmark
- Prior art keywords
- amino acid
- protein
- protein according
- hepta
- positions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2318/00—Antibody mimetics or scaffolds
- C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
Claims (19)
1. Isoleret enkel-kædet protein bestående af formlen HRS1-L1-HRS2-L2-HRS3, hvor HRS1, LI, HRS2, L2 og HRS3 repræsenterer aminosyresekvensfragmenter, som er kovalent forbundet med hinanden, hvor proteinet spontant folder i vandig opløsning således, at HRS1-, HRS2- og HRS3-fragmenterne danner en tripel-strenget, antiparallel, alfa-helisk coiled-coil-struktur, og hvor hver af HRS1, HRS2 og HRS3 uafhængigt er en hepta-repeat-sekvens (ENG: heptad repeat sequence), som er kendetegnet ved et n-gange repeteret 7-rest-mønster af aminosyretyper repræsenteret som (a-b-c-d-e-f-g-)n eller (d-e-f-g-a-b-c-)n og en C-terminal partial hepta-repeat, som ender med en hepta-kernerest anbragt ved en a- eller d-position, hvor mønsterbestanddele 'a' til 'g' betegner konventionelle hepta-positioner ved hvilken aminosyretyperne er anbragt og n er a tal lig med eller større end 2 og mindst 50%, 70%, 90% eller 100% af de konventionelle hepta-positioner 'a' og 'd' er optaget af aminosyrer valgt fra gruppen bestående af valin, isoleucin, leucin, methionin, phenylalanin, tyrosin, tryptofan, histidin, glutamin, threonin, serin, alanin eller derivater deraf, hvor mindst 50%, 70%, 90% eller hvor 100% af de konventionelle hepta-positioner 'b', 'c', 'e', 'f og 'g' er optaget af aminosyrer valgt fra gruppen bestående af glycin, alanin, cystein, serin, threonin, histidin, asparagin, asparaginsyre, glutamin, glutaminsyre, lysin, arginin eller derivater deraf, den fremkomne fordeling af aminosyretyper muliggøre identifikation af hepta-repeat-sekvenserne, og hver af LI og L2 er uafhængigt en linker bestående af 1 til 30 aminosyrerester, denne linker indbefattende en hvilken som helst aminosy-rerest, som utvetydigt ikke kan blive tilordnet til en hepta-repeat-sekvens, og LI og L2 har en aminosyre sammensætning omfattende mindst 50% aminosyrer valgt fra gruppen bestående af glycin, alanin, serin, threonin, prolin eller derivater deraf.
2. Isoleret protein ifølge krav 1, hvor mindst 50%, 70%, 90%, eller hvor 100% af de konventionelle hepta-positioner 'a' og 'd' er optaget af aminosyrer valgt fra gruppen bestående af valin, isoleucin, leucin, methionin eller derivater deraf.
3. Isoleret protein ifølge et hvilket som helst af krav 1 til 2, hvor mindst 50%, 70%, 90% eller hvor 100% af de konventionelle hepta-positioner 'a' og 'd' er optaget af isoleuci-ner.
4. Isoleret protein ifølge et hvilket som helst af krav 1 til 3, hvor LI og L2 har en aminosyresammensætning omfattende mindst 50%, 70%, 90%, eller omfattende 100% aminosyrer valgt fra gruppen bestående af glycin, alanin, cystein, prolin, serin, threonin, histidin, asparagin, asparaginsyre, glutamin, glutaminsyre, lysin, arginin eller derivater deraf.
5. Isoleret protein ifølge et hvilket som helst af krav 1 til 4, hvor LI og L2 har en aminosyresammensætning omfattende mindst 70%, 90% eller omfattende 100% aminosyrer valgt fra gruppen bestående af glycin, alanin, serin, threonin, prolin eller derivater deraf.
6. Isoleret protein ifølge et hvilket som helst af krav 1 til 5, hvor LI og L2 har en aminosyresammensætning omfattende mindst 50%, 70%, 90% eller omfattende 100% glycin og/eller serin-aminosyrer.
7. Isoleret protein ifølge et hvilket som helst af krav 1 til 6, hvor antallet af aminosy-rerester af hver af LI og L2 bliver mindre end halvdelen af antallet af aminosyrerester af hepta-repeat-sekvensen forud for de pågældende LI eller L2.
8. Isoleret protein ifølge et hvilket som helst af krav 1 til 7, hvor aminosyrerester nær enderne af LI og/eller L2 stabiliserer alfa-heliske ender af coiled-coil-strukturen.
9. Isoleret protein ifølge et hvilket som helst af krav 1 til 8, hvor aminosyrerester nær enderne af LI og/eller L2 fremmer dannelsen af et lokal vinding i strukturen.
10. Isoleret protein ifølge et hvilket som helst af krav 1 til 9, hvor konventionel hep-ta-positioner 'e' og 'g' er optaget af glutaminer.
11. Isoleret protein ifølge et hvilket som helst af krav 1 til 10, hvor konventional hepta-positioner 'b', 'c' og 'f er polære, opløselighedsfremmende aminosyrer.
12. Isoleret protein ifølge et hvilket som helst af krav 1 til 11, som folder i vandig opløsning, der har et pH mellem 1 og 13 eller mellem 2 og 12 eller mellem 3 og 11, eller mellem 4 og 10 eller mellem 5 og 9.
13. Isoleret protein ifølge et hvilket som helst af krav 1 til 12, som folder i vandig opløsning, der har en temperatur mellem 0°C og 100°C eller mellem 0°C to 80°C eller mellem 0°C til 60°C.
14. Isoleret protein ifølge et hvilket som helst af krav 1 til 13, som folder i vandig opløsning, der har en ionstyrke mellem 0 og 1,0 molær.
15. Anvendelse af det isolerede protein ifølge et hvilket som helst af krav 1 til 14 som et skelet.
16. Nukleinsyre, der koder for et protein ifølge et hvilket som helst af krav 1 til 14.
17. Vektor omfattende en nukleinsyre ifølge krav 16.
18. Værtscelle omfattende en nukleinsyre eller vektor ifølge krav 16 eller 18.
19. Fremgangsmåde til fremstilling af et protein ifølge et hvilket som helst af krav 1 til 14 omfattende at introducere en nukleinsyre eller vektor i en værtscelle, at dyrke værtscellen i et medium under betingelser, hvor nukleinsyren udtrykkes og proteinet produceres og at isolere proteinet fra værtscellen og/eller mediet.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12064208P | 2008-12-08 | 2008-12-08 | |
| PCT/EP2009/066640 WO2010066740A1 (en) | 2008-12-08 | 2009-12-08 | Single-chain antiparallel coiled coil proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2367840T3 true DK2367840T3 (da) | 2015-10-12 |
Family
ID=41571709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK09774880.0T DK2367840T3 (da) | 2008-12-08 | 2009-12-08 | Enkelt-kædede antiparallelle coiled-coil proteiner |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20110294983A1 (da) |
| EP (1) | EP2367840B1 (da) |
| JP (1) | JP2012510806A (da) |
| CN (1) | CN102245623A (da) |
| AU (1) | AU2009326075B2 (da) |
| BR (1) | BRPI0923346A2 (da) |
| CA (1) | CA2749558C (da) |
| DK (1) | DK2367840T3 (da) |
| ES (1) | ES2547121T3 (da) |
| WO (1) | WO2010066740A1 (da) |
Families Citing this family (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE538129T1 (de) * | 2007-09-07 | 2012-01-15 | Complix N V | Nicht natürliches proteinöses gerüst aus drei nicht kovalent assoziierten peptiden |
| GB2471692A (en) * | 2009-07-08 | 2011-01-12 | Complix Nv | HIV gp41-binding single-chain coiled-coil peptide comprising heptad repeats |
| US8598081B2 (en) | 2010-04-06 | 2013-12-03 | Agrosavfe N.V. | Specific delivery of agrochemicals |
| GB201014715D0 (en) | 2010-09-06 | 2010-10-20 | Vib Vzw | Nanobodies stabilizing functional conformational states of GPCRS |
| WO2012025602A1 (en) | 2010-08-26 | 2012-03-01 | Vib Vzw | Insect binding antibodies |
| ES2634547T3 (es) | 2010-08-26 | 2017-09-28 | Agrosavfe N.V. | Composiciones para el tratamiento de semillas |
| GB201018602D0 (en) | 2010-11-04 | 2010-12-22 | Vib Vzw | MMP8 inactivating antigen binding proteins |
| WO2012084895A2 (en) | 2010-12-20 | 2012-06-28 | Universiteit Gent | Crystal structure of flt3 ligand-receptor complex |
| WO2012092971A1 (en) | 2011-01-06 | 2012-07-12 | Complix Nv | Alphabodies specifically binding to viral proteins and methods for producing the same |
| JP2014504869A (ja) * | 2011-01-06 | 2014-02-27 | コンプリクス エン ヴェー | サイトカインもしくは成長因子および／またはサイトカイン受容体もしくは成長因子受容体に特異的に結合するアルファボディー |
| DK2661446T3 (da) * | 2011-01-06 | 2015-12-21 | Complix Sa | Alphabody-biblioteker og fremgangsmåder til fremstilling deraf |
| US20130261049A1 (en) | 2011-01-06 | 2013-10-03 | Complix Sa | Alphabodies specifically binding to class-i viral fusion proteins and methods for producing the same |
| GB201104469D0 (en) | 2011-03-17 | 2011-04-27 | Univ Gent | Control of phagocytosis |
| EP2723764B1 (en) | 2011-06-21 | 2017-12-27 | Vib Vzw | Binding domains directed against gpcr: g protein complexes and uses derived thereof |
| EP2763529A1 (en) | 2011-10-06 | 2014-08-13 | Agrosavfe N.V. | Manufacturing of specifically targeting microcapsules |
| JP2015504064A (ja) * | 2012-01-06 | 2015-02-05 | コンプリクス エン ヴェー | 細胞内標的分子に対する結合剤 |
| EP2617732A1 (en) | 2012-01-19 | 2013-07-24 | Vib Vzw | Tools and methods for expression of membrane proteins |
| JP6416628B2 (ja) | 2012-01-20 | 2018-10-31 | ブイアイビー ブイゼットダブリュＶｉｂ Ｖｚｗ | 標的変異体αヘリックスバンドルサイトカイン |
| EP2909235B1 (en) | 2012-10-22 | 2017-03-29 | Complix NV | Polypeptides specifically binding to il-23 |
| EP2909233B1 (en) | 2012-10-22 | 2016-12-07 | Complix NV | Polypeptides capable of cellular internalization |
| AU2014211570A1 (en) | 2013-01-29 | 2015-07-23 | The University Court Of The University Of Glasgow | Methods and means for increasing stress tolerance and biomass in plants |
| DK2951201T3 (da) | 2013-01-30 | 2018-01-08 | Vib Vzw | Hidtil ukendte kimære polypeptider til screenings- og lægemiddeldetektionsformål |
| AU2014214054B2 (en) | 2013-02-05 | 2018-10-04 | The Board Of Trustees Of The Leland Stanford Junior University | Muscarinic acetylcholine receptor binding agents and uses thereof |
| PT2992100T (pt) | 2013-04-29 | 2019-12-16 | Agrosavfe Nv | Composições agroquímicas compreendendo anticorpos que se ligam a esfingolípidos |
| EP3431606A1 (en) | 2013-07-01 | 2019-01-23 | Bayer CropScience NV | Methods and means for modulating flowering time in monocot plants |
| US10640542B2 (en) | 2013-07-18 | 2020-05-05 | Vib Vzw | Fusokines involving cytokines with strongly reduced receptor binding affinities |
| SG10202010429YA (en) | 2013-07-19 | 2020-11-27 | Vib Vzw | Targeting of cytokine antagonists |
| CA2918518C (en) | 2013-07-19 | 2022-08-16 | Universiteit Gent | Targeted modified il-1 family members |
| BR112016001114B1 (pt) | 2013-07-19 | 2023-02-14 | Vib Vzw | Composição compreendendo uma proteína de fusão e uso da referida composição |
| WO2015097289A1 (en) | 2013-12-24 | 2015-07-02 | Vib Vzw | Secretion and functional display of chimeric polypeptides |
| GB201400997D0 (en) | 2014-01-21 | 2014-03-05 | Vib Vzw | Targeting of interleukin-1 and -18 in treatment of septic shock |
| EP3099707B1 (en) | 2014-01-30 | 2021-12-29 | Vib Vzw | Opioid receptor binding agents and uses thereof |
| EP3126393B1 (en) | 2014-03-31 | 2019-09-11 | Vib Vzw | A method of treating bone disease |
| CA2955554C (en) | 2014-07-22 | 2022-07-05 | Vib Vzw | Methods to select for agents that stabilize protein complexes |
| WO2016050512A1 (en) | 2014-10-03 | 2016-04-07 | Bayer Cropscience Nv | Methods and means for increasing stress tolerance and biomass in plants |
| JP7089877B2 (ja) | 2014-11-05 | 2022-06-23 | バイオタリス・エン・フェー | 重鎖抗体の可変ドメインをコードするポリヌクレオチドを含むトランスジェニック植物 |
| JP6730705B2 (ja) * | 2015-02-12 | 2020-07-29 | 国立大学法人岩手大学 | 哺乳動物細胞に対する外来遺伝子の導入効率の向上剤 |
| EP3371311B1 (en) | 2015-11-06 | 2021-07-21 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| EP3978010A1 (en) | 2015-12-02 | 2022-04-06 | Fred Hutchinson Cancer Research Center | Circular tandem repeat proteins |
| EP3998281A1 (en) | 2016-02-05 | 2022-05-18 | Orionis Biosciences BV | Cd8 binding agents |
| US11661455B2 (en) | 2016-02-05 | 2023-05-30 | Orionis Biosciences BV | Chimeric protein comprising an interferon alpha 2mutant and a PD-L1 binding moiety |
| EP3426278B1 (en) | 2016-03-07 | 2024-01-03 | Vib Vzw | Cd20 binding single domain antibodies |
| WO2017173356A1 (en) | 2016-04-01 | 2017-10-05 | University Of Washington | Polypeptides capable of forming homo-oligomers with modular hydrogen bond network-mediated specificity and their design |
| JP7105200B2 (ja) | 2016-05-13 | 2022-07-22 | オリオニス バイオサイエンシズ ビーブイ | 標的突然変異体インターフェロン－ベータおよびその使用 |
| WO2017194782A2 (en) | 2016-05-13 | 2017-11-16 | Orionis Biosciences Nv | Therapeutic targeting of non-cellular structures |
| CA3039364A1 (en) * | 2016-10-04 | 2018-04-12 | University Of Florida Research Foundation, Inc. | Targeted effector proteins and uses thereof |
| ES2917000T3 (es) | 2016-10-24 | 2022-07-06 | Orionis Biosciences BV | Interferón-gamma mutante diana y usos del mismo |
| KR102642385B1 (ko) | 2017-02-06 | 2024-03-04 | 오리오니스 바이오사이언시스 엔브이 | 표적화된 키메라 단백질 및 이의 용도 |
| US10906985B2 (en) | 2017-02-06 | 2021-02-02 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| EP3601367A4 (en) | 2017-03-30 | 2020-09-16 | The University of Queensland | CHEMERICAL MOLECULES AND ASSOCIATED USES |
| EP3415010A1 (en) | 2017-06-13 | 2018-12-19 | Agrosavfe Nv | Insect-controlling polypeptides and methods |
| WO2019032661A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | CD8 LIAISON AGENTS |
| WO2019032663A1 (en) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | PD-1 AND PD-L1 BINDING AGENTS |
| US11407797B2 (en) | 2017-10-11 | 2022-08-09 | University Of Florida Research Foundation, Incorporated | Modified gal-1 proteins and uses thereof |
| CA3133643A1 (en) | 2019-03-28 | 2020-10-01 | Orionis Biosciences, Inc. | Therapeutic interferon alpha 1 proteins |
| SG11202111830UA (en) | 2019-04-29 | 2021-11-29 | Confo Therapeutics N V | Chimeric proteins and methods to screen for compounds and ligands binding to gpcrs |
| WO2021140205A1 (en) | 2020-01-10 | 2021-07-15 | Confo Therapeutics N.V. | Methods for generating antibodies and antibody fragments and libraries comprising same |
| CA3178461A1 (en) | 2020-03-31 | 2021-10-07 | Biotalys NV | Anti-fungal polypeptides |
| CN112382336B (zh) * | 2020-12-01 | 2023-09-01 | 北京晶泰科技有限公司 | 一种小蛋白骨架设计方法及其应用 |
| EP4267167A2 (en) * | 2020-12-28 | 2023-11-01 | New York University | Crosslinked helix dimer mimics of sos and methods of using same |
| WO2023057601A1 (en) | 2021-10-06 | 2023-04-13 | Biotalys NV | Anti-fungal polypeptides |
| WO2023203127A1 (en) | 2022-04-20 | 2023-10-26 | Vib Vzw | Alphabody-based degrader molecules |
| WO2024038183A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
| WO2024038193A1 (en) | 2022-08-18 | 2024-02-22 | Immunocore Limited | Multi-domain binding molecules |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20080027006A1 (en) * | 2004-02-12 | 2008-01-31 | The Regents Of The University Of Colorado | Compositions And Methods For Modification And Prevention Of Sars Coronavirus Infectivity |
| ATE538129T1 (de) | 2007-09-07 | 2012-01-15 | Complix N V | Nicht natürliches proteinöses gerüst aus drei nicht kovalent assoziierten peptiden |
| EP2161278B1 (en) * | 2008-09-08 | 2012-05-23 | Complix N.V. | Single-chain coiled coil scaffold |
-
2009
- 2009-12-08 AU AU2009326075A patent/AU2009326075B2/en active Active
- 2009-12-08 DK DK09774880.0T patent/DK2367840T3/da active
- 2009-12-08 CN CN2009801493431A patent/CN102245623A/zh active Pending
- 2009-12-08 JP JP2011539056A patent/JP2012510806A/ja active Pending
- 2009-12-08 US US13/133,309 patent/US20110294983A1/en not_active Abandoned
- 2009-12-08 CA CA2749558A patent/CA2749558C/en active Active
- 2009-12-08 BR BRPI0923346A patent/BRPI0923346A2/pt not_active Application Discontinuation
- 2009-12-08 ES ES09774880.0T patent/ES2547121T3/es active Active
- 2009-12-08 EP EP09774880.0A patent/EP2367840B1/en active Active
- 2009-12-08 WO PCT/EP2009/066640 patent/WO2010066740A1/en active Application Filing
-
2015
- 2015-08-21 US US14/832,039 patent/US20160039867A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2010066740A1 (en) | 2010-06-17 |
| US20160039867A1 (en) | 2016-02-11 |
| EP2367840B1 (en) | 2015-08-12 |
| CA2749558C (en) | 2019-01-15 |
| AU2009326075A1 (en) | 2011-06-30 |
| CA2749558A1 (en) | 2010-06-17 |
| CN102245623A (zh) | 2011-11-16 |
| AU2009326075B2 (en) | 2014-06-05 |
| EP2367840A1 (en) | 2011-09-28 |
| BRPI0923346A2 (pt) | 2017-07-11 |
| ES2547121T3 (es) | 2015-10-01 |
| US20110294983A1 (en) | 2011-12-01 |
| JP2012510806A (ja) | 2012-05-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2367840T3 (da) | Enkelt-kædede antiparallelle coiled-coil proteiner | |
| US9217011B2 (en) | Non-natural proteinaceous scaffold made of three non-covalently associated peptides | |
| EP2161278B1 (en) | Single-chain coiled coil scaffold | |
| US9775912B2 (en) | Designed repeat proteins binding to serum albumin | |
| EP2198022B1 (en) | Designed armadillo repeat proteins | |
| EP4074727A1 (en) | N-terminal capping modules of ankyrin repeat domains | |
| Boudko et al. | Design and crystal structure of bacteriophage T4 mini-fibritin NCCF | |
| Kim et al. | Designed leucine‐rich repeat proteins bind two muramyl dipeptide ligands | |
| US20240043481A1 (en) | N-Terminal Capping Modules of Ankyrin Repeat Domains | |
| Tavenor | Supramolecular Architectures and Mimics of Complex Natural Folds Derived from Rationally Designed α-Helical Protein Structures | |
| Qi et al. | Terminal Repeats in Collagen Triple-Helices | |
| Thomas | X-Ray Crystallography as a Tool for the Structural Study and Design of α/β-Peptides |